PMID- 12644005
OWN - NLM
STAT- MEDLINE
DCOM- 20030814
LR  - 20190513
IS  - 1388-9842 (Print)
IS  - 1388-9842 (Linking)
VI  - 5
IP  - 2
DP  - 2003 Mar
TI  - Bedside B-type natriuretic peptide and functional capacity in chronic heart 
      failure.
PG  - 155-60
AB  - OBJECTIVES: To determine if B-type natriuretic peptide (BNP) measurement could be 
      useful in determination of functional capacity in patients suffering from chronic 
      heart failure. BACKGROUND: Evaluating functional capacity is a crucial factor in 
      the follow-up of patients with chronic heart failure. There are numerous methods 
      for measuring functional capacity and their relative merits remain under 
      discussion. Clinical classifications are very subjective and other methods are 
      difficult to use in clinical practice. METHODS: We evaluated functional capacity 
      in 151 consecutive patients using the 6-min walk test. All patients were 
      clinically classified using the New York Heart Association (NYHA) classification. 
      We measured BNP plasma levels using a bedside BNP test. RESULTS: Six minute walk 
      test performance decreased through NYHA classes 1 to 4 (469+/-87, 411+/-82, 
      325+/-83 and 196+/-63 m, respectively, P<0.01) and BNP levels increased through 
      NYHA classes 1 to 4 (26.3+/-7.2, 73+/-13, 401+/-74 and 924+/-84 pg/ml, 
      respectively, P<0.001). There was a significant correlation between 6-min walk 
      test performance and BNP plasma levels (R=0.69 P<0.001) and a weaker correlation 
      between BNP and left ventricular ejection fraction (R=0.45 P<0.04). In some 
      patients there was a mismatch between NYHA classification and 6-min walk test 
      performance. In all cases BNP could correct the clinical estimation of functional 
      capacity. When we divided the patients into three sub-groups within each NYHA 
      class, we showed that using BNP could better define functional capacity in 
      patients suffering from chronic heart failure in NYHA classes I to III. 
      CONCLUSION: The measurement of BNP levels thus usefully supplements the clinical 
      examination. The existence of bedside BNP testing methods facilitates its use in 
      routine clinical practice. It also permits easier follow-up of patients with 
      chronic heart failure.
FAU - Jourdain, P
AU  - Jourdain P
AD  - Service de Cardiologie Centre Hospitalier Rene Dubos, 6 avenue d'Ile de France 
      95300, Pontoise, France. patrickjourdain@hotmail.com
FAU - Funck, F
AU  - Funck F
FAU - Bellorini, M
AU  - Bellorini M
FAU - Guillard, N
AU  - Guillard N
FAU - Loiret, J
AU  - Loiret J
FAU - Thebault, B
AU  - Thebault B
FAU - Desnos, M
AU  - Desnos M
FAU - Duboc, D
AU  - Duboc D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Biomarkers)
RN  - 0 (Carbazoles)
RN  - 0 (Diuretics)
RN  - 0 (Propanolamines)
RN  - 0K47UL67F2 (Carvedilol)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 27O7W4T232 (Spironolactone)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
RN  - E7199S1YWR (Lisinopril)
SB  - IM
MH  - Adolescent
MH  - Adrenergic beta-Antagonists/administration & dosage
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage
MH  - Atrial Natriuretic Factor/*blood/drug effects
MH  - Biomarkers/blood
MH  - Carbazoles/administration & dosage
MH  - Carvedilol
MH  - Chronic Disease
MH  - Diuretics/administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Follow-Up Studies
MH  - France/epidemiology
MH  - Furosemide/administration & dosage
MH  - Heart Failure/*blood/classification/*physiopathology
MH  - Humans
MH  - Incidence
MH  - Lisinopril/administration & dosage
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain
MH  - Propanolamines/administration & dosage
MH  - Severity of Illness Index
MH  - Spironolactone/administration & dosage
MH  - Stroke Volume/physiology
MH  - Treatment Outcome
EDAT- 2003/03/20 04:00
MHDA- 2003/08/15 05:00
CRDT- 2003/03/20 04:00
PHST- 2003/03/20 04:00 [pubmed]
PHST- 2003/08/15 05:00 [medline]
PHST- 2003/03/20 04:00 [entrez]
AID - S1388984202002477 [pii]
AID - 10.1016/s1388-9842(02)00247-7 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2003 Mar;5(2):155-60. doi: 10.1016/s1388-9842(02)00247-7.